StreetInsider.com News Articles

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

Mon, 09 Feb 2026 03:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents".

The international patent application covers innovative methods and formulations aimed at addressing longstanding challenges in the treatment of neurological diseases and disorders. Of particular interest is Parkinson's disease, which is a neurodegenerative condition afflicting over 10 to 12 million globally, and it is cited as the 2^nd most common neurodegenerative disorder after dementia. Progressive

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

Mon, 09 Feb 2026 03:00:00 -0500

PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement

Wed, 26 Nov 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") and BioGene Therapeutics Inc. ("BioGene"), are pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025, October 20, 2025 and November 20, 2025, the previously announced plan of arrangement (the "Arrangement") involving the spin-off of 12,000,000 shares of BioGene from PreveCeutical became effective November 25, 2025.

The Arrangement

The Arrangement was approved by the shareholders

PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement

Wed, 26 Nov 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

The Arrangement

The Arrangement was approved by the shareholders

PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.

Thu, 20 Nov 2025 12:26:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 2025 will be issued new common shares of PreveCeutical and 0.02 of one share of BioGene Therapeutics Inc.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including:

PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.

Thu, 20 Nov 2025 12:26:00 -0500

About PreveCeutical

PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.

Thu, 20 Nov 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025 and October 20, 2025, the Company announces that it will be completing its previously announced plan of arrangement (the "Arrangement") to be effected under Part 9, Division 5 of the Business Corporations Act (British Columbia) with BioGene Therapeutics Inc. ("BioGene") effective Monday, November 24, 2025.

PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.

Thu, 20 Nov 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

PreveCeutical closes $455,000 second tranche of private placement

Thu, 30 Oct 2025 07:03:21 -0500

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) completed the second tranche of its non-brokered private placement, raising $455,000 through the issuance of 11,375,000 units at $0.04 per unit.

Each unit consists of one common share and one-half share purchase warrant. The warrants allow holders to purchase additional shares at $0.06 each for 24 months from the closing date. The company retains an acceleration right to shorten the warrant expiry period if shares trade at $0.18 or higher for 10 consecutive trading days on the Canadian Securities Exchange.

The Vancouver-based company paid $29,200 in finder's fees and issued 730,000 finder's warrants

PreveCeutical Closes Second Tranche of Non-Brokered Private Placement

Thu, 30 Oct 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche") of its previously announced $1,200,000 non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 11,375,000 units (each, a "Unit") of the Company at a price of $0.04 per Unit

PreveCeutical Closes Second Tranche of Non-Brokered Private Placement

Thu, 30 Oct 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.

Mon, 20 Oct 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025 and October 10, 2025, it will be proceeding to complete its previously announced plan of arrangement (the "Arrangement") to be effected under Part 9, Division 5 of the Business Corporations Act (British Columbia) with BioGene Therapeutics Inc. ("BioGene").

On September 9, 2025, the Company obtained an interim

PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.

Mon, 20 Oct 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

On September 9, 2025, the Company obtained an interim

PreveCeutical increases private placement to $1.2 million

Fri, 10 Oct 2025 16:02:13 -0500

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) announced the approval of all resolutions at its annual general and special meeting held October 10, 2025, and increased the size of its non-brokered private placement financing.

The Vancouver-based health sciences company reported that shareholders approved the election of four directors: Stephen Van Deventer, Makarand Jawadekar, Kathleen Rokita and C. Evan Ballantyne. The meeting also ratified Davidson & Company LLP as auditors for fiscal years ending December 31, 2024 and 2025.

Shareholders approved a plan of arrangement under British Columbia's Business Corporations Act to distribute up to 12 million common shares of BioGene

PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement

Fri, 10 Oct 2025 16:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that all resolutions presented at the Company's annual general and special meeting (the "Meeting") held on Friday, October 10, 2025, including the following:

the election of Stephen Van Deventer, Makarand Jawadekar, Kathleen Rokita and C. Evan Ballantyne as directors of the Company;
the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the auditors of PreveCeutical for the financial year ending December 31, 2024 and 2025;
a plan of arrangement under

PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement

Fri, 10 Oct 2025 16:00:00 -0500

the election of Stephen Van Deventer, Makarand Jawadekar, Kathleen Rokita and C. Evan Ballantyne as directors of the Company;
the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the auditors of PreveCeutical for the financial year ending December 31, 2024 and 2025;
a plan of arrangement under

PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics

Fri, 19 Sep 2025 18:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information circular dated September 9, 2025 and related meeting materials of the Company (the "Meeting Materials") for use at the annual general and special meeting (the "Meeting") of shareholders of PreveCeutical (the "PreveCeutical Shareholders") to be held in connection with the proposed plan of arrangement (the "Arrangement") to be effected under Part 9, Division 5 of the

PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics

Fri, 19 Sep 2025 18:00:00 -0500

PreveCeutical closes initial tranche of private placement for $646,500

Fri, 05 Sep 2025 17:00:14 -0500

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has closed the initial tranche of its previously announced $1 million non-brokered private placement, raising $646,500 in gross proceeds.

The Vancouver-based health sciences company issued 16,162,500 units at $0.04 per unit. Each unit consists of one common share and half of one share purchase warrant. The warrants allow holders to purchase additional shares at $0.06 each for 24 months from the closing date.

The warrants include an acceleration provision that allows PreveCeutical to shorten the expiry period if its shares trade at $0.18 or higher on the Canadian Securities Exchange for at least

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Fri, 05 Sep 2025 16:58:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated August 5, 2025, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 16,162,500 units (each, a "Unit") of the Company at a price of $0.04 per Unit for gross aggregate proceeds of $646,500.

Each Unit is comprised of one (1) common share (each, a "Share") in the capital of the Company and

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Fri, 05 Sep 2025 16:58:00 -0500

Each Unit is comprised of one (1) common share (each, a "Share") in the capital of the Company and

PreveCeutical Announces Arrangement Agreement with BioGene Therapeutics

Thu, 04 Sep 2025 16:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") dated September 3, 2025 with its subsidiary, BioGene Therapeutics Inc. ("BioGene"), pursuant to which PreveCeutical intends to spin-out 12,000,000 common shares of BioGene (the "BioGene Spinout Shares") to the shareholders of PreveCeutical (the "PreveCeutical Shareholders") on a pro rata basis by way of a share capital reorganization effected through a statutory plan of arrangement (the "Arrangement") pursuant to the Business Corporations Act (British Columbia) (the "BCBCA"). PreveCeutical

PreveCeutical Announces Arrangement Agreement with BioGene Therapeutics

Thu, 04 Sep 2025 16:00:00 -0500

PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Director Resignation

Thu, 28 Aug 2025 18:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - August 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that, further to its News Release of June 25, 2025, July 8, 2025 and August 5, 2025, it has rescheduled its annual general and special meeting (the "Meeting") from September 29, 2025 to October 10, 2025 due to the necessity to comply with the various requirements in connection with the proposed plan of arrangement. At the Meeting, the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve:

(i)

PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Director Resignation

Thu, 28 Aug 2025 18:00:00 -0500

(i)